Littlepage, L.E., A. S. Adler, H. Kouros-Mehr, G. Huang, J. Chou, S. R. Krig, O. L. Griffith, J. E. Korkola, K. Qu, D. A. Lawson, Q. Xue, M. D. Sternlicht, G. J. P. Dijkgraaf, P. Yaswen, Hope. S. Rugo, C. A. Sweeney, C. C. Collins, J. W. Gray, H. Y. Chang & Z. Werb. The transcription factor ZNF217 is a prognostic biomarker and therapeutic target during breast cancer progression. Cancer Discov. 2012 Jul;2(7):638-51. - Stand Up To Cancer

Blog

Posted September 4, 2019

Littlepage, L.E., A. S. Adler, H. Kouros-Mehr, G. Huang, J. Chou, S. R. Krig, O. L. Griffith, J. E. Korkola, K. Qu, D. A. Lawson, Q. Xue, M. D. Sternlicht, G. J. P. Dijkgraaf, P. Yaswen, Hope. S. Rugo, C. A. Sweeney, C. C. Collins, J. W. Gray, H. Y. Chang & Z. Werb. The transcription factor ZNF217 is a prognostic biomarker and therapeutic target during breast cancer progression. Cancer Discov. 2012 Jul;2(7):638-51.

JOIN OUR COMMUNITY

Sign up to receive emails from Stand Up To Cancer.
   Please leave this field empty
Stand Up to Cancer

Thanks for signing up!
You will hear from us soon.